Protein Expressions and Genetic Variations of SLC5A8 in Prostate Cancer Risk and Aggressiveness
Protein Expressions and Genetic Variations of SLC5A8 in Prostate Cancer Risk and Aggressiveness
复制标题
DOI：
10.1016/j.urology.2011.04.055
复制
发表时间：
2011-10-01
期刊：
影响因子：
2.1
通讯作者：
Park, Jong Y.
中科院分区：
文献类型：
--
作者：
Lin, Hui-Yi;Park, Hyun Y.;Park, Jong Y.
目的研究SLC 5A 8基因在前列腺癌组织中的表达及单核苷酸多态性，探讨SLC 5A 8基因在前列腺癌发病中的作用。以前的研究表明，SLC 5A 8可能作为一个肿瘤抑制基因，其沉默的表观遗传变化可能有助于cancerogenetic.METHODS我们构建了组织芯片从183前列腺肿瘤组织，43个相邻的非肿瘤组织从相同的患者，和13个组织样本从良性前列腺增生或前列腺上皮内瘤变患者。SLC 5A 8蛋白表达的半定量评估确定为免疫染色强度和染色细胞百分比的乘积。此外，我们还比较了668例前列腺癌患者和385例对照组中SLC 5A 8基因4个单核苷酸多态性位点（rs 164365，rs 1709189，rs 1399236和rs 1681096）的频率。在Moffitt样本中，我们观察到rs 164365基因型中含有>= 1个“A”等位基因的患者的临界中度风险增加（优势比1.35，95%置信区间1.00-1.80），特别是在高个子男性（>= 70 in.;比值比1.80，95%置信区间1.20-2.68）。然而，这些结果并没有得到证实，在癌症遗传标记的易感性population.CONCLUSION这些数据表明，SLC 5A 8的表达模式可能会被用作一个诊断生物标志物，并需要一个更大的研究，以评估SLC 5A 8单核苷酸多态性在前列腺癌的重要性。泌尿学78：971.e1-971.e9，2011年。(C)2011 Elsevier Inc.
OBJECTIVE To understand the role in prostate cancer risk and aggressiveness, we investigated the expression in prostate tumor and single nucleotide polymorphisms of SLC5A8. Previous studies have suggested that SLC5A8 might function as a tumor suppressor gene, whose silencing by epigenetic changes might contribute to carcinogenesis.METHODS We constructed tissue microarrays from 183 prostate tumor tissues, 43 adjacent non-neoplastic tissues from the same patients, and 13 tissue samples from patients with benign prostatic hyperplasia or prostatic intraepithelial neoplasia. A semiquantitative assessment of SLC5A8 protein expression was determined as the product of immunostaining intensity and the percentage of cells stained. In addition, we compared the frequencies of 4 single nucleotide polymorphisms (rs164365, rs1709189, rs1399236, and rs1681096) in SLC5A8 between 668 prostate cancer cases and 385 controls.RESULTS SLC5A8 expression was significantly greater in the tumor tissues than in the paired nonneoplastic tissues (P < .0001). In the Moffitt samples, we observed a borderline moderate risk increase in patients with a genotype containing >= 1 "A" allele of rs164365 (odds ratio 1.35, 95% confidence interval 1.00-1.80), especially among tall men (>= 70 in.; odds ratio 1.80, 95% confidence interval 1.20-2.68). However, these results were not confirmed in the Cancer Genetic Markers of Susceptibility population.CONCLUSION These data suggest that the expression pattern of SLC5A8 might be used as a diagnostic biomarker, and a larger study is required to assess the importance of SLC5A8 single nucleotide polymorphisms in prostate cancer. UROLOGY 78: 971.e1-971.e9, 2011. (C) 2011 Elsevier Inc.